The Institute for Bioengineering of Catalonia (IBEC) is looking for Master candidates to apply for Master fellowships within the IBEC Master Programme for 2025. IBEC launches the 9th call of the Master Programme … Read more
IBEC is committed to turning research results into practical applications, providing innovative solutions to industry and to hospitals, and, ultimately, to society. We carry out Market-Driven Technology Transfer, managing our … Read more
IBEC’s Core Facilities have been included in MINECO’s updated ICTS (Infraestructuras Científicas y Técnicas Singulares) map as part of NANBIOSIS, an integrated platform for research-oriented medical applications. Created by combining the service platforms within the CIBER-BBN and CCMIJU (the Center for Minimally Invasive Surgery Jesus Uson), NANBIOSIS (Infraestructuras Integrada de Producción y Caracterización de Nanomateriales, Biomateriales y Sistemas en Biomedicina) aims to be a ‘one-stop-shop’ service facility for the design and production of biomaterials and nanomaterials, among other applications.
Josep A. Planell, rector of the UOC and Research Fellow at IBEC, appears in a new documentary about technology transfer in Catalonia, Inversió de Futur.Presented by Pere Estupinyà, the hour-long documentary, made in by Televisió de Catalunya in collaboration with the CERCA centers, also features other notable names in the Catalan research arena, such as Hble. Sr. Andreu Mas-Colell and director of the PCB Montserrat Vendrell.
IBEC is participating this week in Expoquimia, the international chemistry trade show whose 17th edition is taking place from 30 September to 3 October at the Fira Gran Via in Barcelona.Expoquimia is attended by the leading companies and organizations in the international chemical industry such as BASF, BAYER, Dow Chemical, ICL, REPSOL and SOLVAY. The Fira’s three halls open their doors at 10am today, kicking off a program of workshops, seminars and conferences, as well as the trade exhibition.
An article by Raimon Jané appears in this month’s edition of IEEE Pulse, the magazine of the IEEE Engineering in Medicine and Biology Society, which is devoted to the science of sleep.
Two groups working together at IBEC demonstrate the potential of electrical studies of single bacterial cells in a paper published in ACS Nano.Gabriel Gomila’s Nanoscale Bioelectrical Characterization group and that of Antonio Juárez, Microbial Biotechnology and Host-pathogen Interaction, combined their expertise on microscopic electrical measurements and bacteria respectively to come up with a way to study the response to external electrical fields of just a single bacterial cell.
The 7th annual IBEC Symposium is fast approaching!This year the theme will be ‘Bioengineering for Future Medicine’, which is one of the institute’s three main areas of application.
Researchers in IBEC’s Nanoprobes and Nanoswitches group and their collaborators have announced the development of the first ever light-controlled therapeutic agent whose effects focus specifically on the largest, most important class of drug target proteins – G protein-coupled receptors.In the journal Nature Chemical Biology this week, the scientists reveal Alloswitch-1, the latest advance in their research into photoswitchable (or light-operated) drugs. Controlling drug activity with light means that the therapeutic effects can be accurately delivered locally, thus reducing their effect on other areas and the resultant side effects, and helps reduce the dosage required.
Application Deadline:05/01/2017